-DigiTimes
On Saturday December 10th Kura Oncology Presents Updated Clinical Data From KOMET-001 Trial Of Menin Inhibitor Ziftomenib At American Society Of Hematology Annual Meeting
– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML –
– Low frequency of differentiation syndrome, including 5% rate (1/20) of ≥ Grade 3 among
